TRUFFRed Light Holland Corp

Most clinical trials in psychedelic medicine have traditionally focused on the impact of a single treatment session. However, new data published this month is shifting that narrative, suggesting that psilocybin therapy may be more effective when structured as a repeatable, protocol-driven treatment rather than a one-time intervention. As regulatory pathways for these therapies accelerate, the focus is moving toward optimizing dosing schedules to maximize long-term patient outcomes. Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) released details today of a Phase 1 clinical study ...

Most clinical trials in psychedelic medicine have traditionally focused on the impact of a single treatment session. However, new data published this month is shifting that narrative, suggesting that psilocybin therapy may be more effective when structured as a repeatable, protocol-driven treatment rather than a one-time intervention. As regulatory pathways for these therapies accelerate, the focus is moving toward optimizing dosing schedules to maximize long-term patient outcomes. Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) released details today of a Phase 1 clinical study ...

Most clinical trials in psychedelic medicine have traditionally focused on the impact of a single treatment session. However, new data published this month is shifting that narrative, suggesting that psilocybin therapy may be more effective when structured as a repeatable, protocol-driven treatment rather than a one-time intervention. As regulatory pathways for these therapies accelerate, the focus is moving toward optimizing dosing schedules to maximize long-term patient outcomes. Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) released details today of a Phase 1 clinical study ...